In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).
No takes yet. Share an insight, caveat, or question.
Gerwin A Huls (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: